{"editorial":{"content_id":"aebbeb5a-8e71-42cc-b809-cbd036b21528","slug":"anvisa-20261102-307217","content_type":"news","title":"巴西Anvisa参与全球药物不良反应报告宣传活动","summary":"巴西国家卫生监督局于2026年11月2日至8日参与#MedSafetyWeek 2026国际宣传活动，呼吁公众报告药物不良反应。","body":"巴西国家卫生监督局（Anvisa）于2026年11月2日至8日参与#MedSafetyWeek 2026国际宣传活动，该活动汇集全球监管机构和卫生组织，旨在提高公众对报告药物不良反应重要性的认识。今年活动主题为“不良反应：不要忽视，请报告”。\n\nAnvisa表示，药物在预防和治疗疾病方面发挥作用，但与其他健康干预措施一样，也可能引起不良反应，有些立即出现，有些则可能逐渐显现，甚至在长期使用后出现。患者、卫生专业人员及其他公民的报告对于持续监测药物安全至关重要，有助于识别新风险、加深对已上市产品的了解，并为保护公众健康的措施提供依据。\n\nAnvisa药物警戒经理Viviane Vilela表示：“公众和卫生专业人员提交的报告在药物安全监测中发挥重要作用。每一份报告都拓展了对这些产品使用相关潜在风险的了解，并可能有助于保护其他人免受未来伤害。”\n\nAnvisa邀请患者、卫生专业人员及全社会关注可能的不良反应，并在发生时及时报告。2026年#MedSafetyWeek是迄今规模最大的一届，超过120个国家的130多个组织将在活动期间以60多种语言分享宣传内容。","why_it_matters":null,"cbi_observation":null,"direction_tag":"巴西","primary_category":"科技平台","secondary_topics":["合规","政策","br-health"],"content_level":"编辑整理","event_type":"公共事件","audience_tags":[],"event_location":null,"verification_status":"source_verified","published_at":"2026-11-02T11:00:59.976Z","display_date":"2026-11-02","source_published_at":null,"source_url":"https://www.gov.br/anvisa/pt-br/assuntos/noticias-anvisa/2026/brasil-participa-de-campanha-global-que-incentiva-a-notificacao-de-efeitos-adversos-a-medicamentos","source_name":"Anvisa","source_language":"pt","author_name":"编辑部","risk_level":"low","risk_flags":[],"opportunity_flags":[],"trend_signals":["international_regulatory_collaboration","pharmacovigilance_public_education"]},"intelligence":{"intel_id":"bf5436d9-ddf2-4240-8d22-31a5350f2150","version":1,"event_type":"监管表态","event_date":"2026-11-02","main_entities":[{"name":"巴西国家卫生监督局（Anvisa）","role":"参与#MedSafetyWeek 2026并呼吁公众报告药物不良反应","type":"regulator","country":"巴西","normalized_name":null},{"name":"#MedSafetyWeek 2026","role":"汇集全球监管机构和卫生组织的国际药物安全宣传活动的平台","type":"platform","country":"其他","normalized_name":null},{"name":"Viviane Vilela","role":"Anvisa药物警戒经理，强调报告对药物安全监测的重要性","type":"person","country":"巴西","normalized_name":null}],"main_action":"Anvisa参与#MedSafetyWeek 2026并呼吁公众及时报告药物不良反应","key_numbers":[{"unit":"个","label":"参与国家数","value":"120"},{"unit":"个","label":"参与组织数","value":"130"},{"unit":"种","label":"宣传语言数","value":"60"}],"facts":[{"verified":false,"statement":"Anvisa于2026年11月2日至8日参与#MedSafetyWeek 2026国际宣传活动。","source_excerpt":null},{"verified":false,"statement":"2026年#MedSafetyWeek主题为“不良反应：不要忽视，请报告”。","source_excerpt":null},{"verified":false,"statement":"Anvisa表示，患者、卫生专业人员及其他公民的报告对持续监测药物安全至关重要。","source_excerpt":null},{"verified":false,"statement":"2026年#MedSafetyWeek有超过120个国家的130多个组织以60多种语言分享宣传内容。","source_excerpt":null}],"assessments":[{"statement":"Anvisa此次参与属于药物警戒领域的监管沟通与公众教育，而非新政策发布。","confidence":"high","basis_fact_index":null},{"statement":"全球参与规模显示药物不良反应报告领域的国际协作和公众教育力度较大。","confidence":"medium","basis_fact_index":null},{"statement":"公众报告意识提升可能增加在巴医药企业药物警戒数据管理和合规关注度。","confidence":"medium","basis_fact_index":null}],"actions":[{"target":"both","priority":"normal","description":"持续跟踪Anvisa药物警戒公告及#MedSafetyWeek 2026成果发布。"},{"target":"user","priority":"high","description":"建议在巴医药企业复核药物不良反应报告流程、时限和药物警戒责任分工。"},{"target":"system","priority":"normal","description":"系统将Anvisa、药物警戒和不良反应报告列入巴西医疗健康监管监测关键词。"}],"affected_audience":["患者","卫生专业人员","公众","在巴医药企业"],"risk_flags":[],"opportunity_flags":[],"trend_signals":["international_regulatory_collaboration","pharmacovigilance_public_education"],"follow_up_needed":true,"follow_up_questions":["Anvisa是否在#MedSafetyWeek 2026期间发布新的药物不良反应报告渠道或指南？","2026年#MedSafetyWeek结束后是否有参与数据或活动成果发布？","巴西药物警戒报告要求是否对在巴医药企业产生新的合规关注点？"],"related_topics":["药物警戒","药物不良反应报告","Anvisa","MedSafetyWeek","公众健康","国际监管合作"],"verification_status":"unverified","confidence_score":0.7,"generated_at":"2026-11-02T11:01:18.548Z"},"meta":{"canonical_url":"https://chinabrazilinsight.com/news/anvisa-20261102-307217","api_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261102-307217","markdown_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261102-307217?view=markdown","json_url":"https://chinabrazilinsight.com/api/public/content/anvisa-20261102-307217?view=json","last_updated":"2026-11-02T11:01:19.183Z","platform":"China Brazil Insight","platform_url":"https://chinabrazilinsight.com"}}